RT Journal Article
T1 Open-label, phase 2 study of blinatumomab after frontline R-chemotherapy in adults with newly diagnosed, high-risk DLBCL.
A1 Katz, Deborah A
A1 Morris, Joan D
A1 Chu, Michael P
A1 David, Kevin A
A1 Thieblemont, Catherine
A1 Morley, Nicholas J
A1 Khan, Sharif S
A1 Viardot, Andreas
A1 Martín García-Sancho, Alejandro
A1 Rodríguez-García, Guillermo
A1 Bastos-Oreiro, Mariana
A1 Lee, Seung Tae
A1 Kormany, William
A1 Chen, Yuqi
A1 Wong, Hansen L
A1 Anderson, Abraham A
A1 Katlinskaya, Yuliya
A1 Avilion, Ariel A
A1 Dai, Tian
A1 González-Barca, Eva
K1 Relapsed/refractory
K1 blinatumomab
K1 high-risk DLBCL
AB This open-label, multicenter, single-arm, phase 2 study assessed the safety and efficacy of blinatumomab consolidation therapy in adult patients with newly diagnosed, high-risk diffuse large B-cell lymphoma (DLBCL; International Prognostic Index 3-5 and/or double-/triple-hit or double MYC/BCL-2 expressors) who achieved complete response (CR), partial response (PR), or stable disease (SD) following run-in with 6 cycles of R-chemotherapy (NCT03023878). Of the 47 patients enrolled, 28 received blinatumomab. Five patients (17.9%) experienced grade 4 treatment-emergent adverse events of interest (neutropenia, n = 4; infection, n = 1). Two deaths reported at the end of the study were unrelated to treatment with blinatumomab (disease progression, n = 1; infection, n = 1). 3/4 patients with PR and 4/4 patients with SD after R-chemotherapy achieved CR following blinatumomab. Consolidation with blinatumomab in patients with newly diagnosed, high-risk DLBCL who did not progress under R-chemotherapy was better tolerated than in previous studies where blinatumomab was used for treatment of patients with lymphoma.
YR 2022
FD 2022-05-03
LK http://hdl.handle.net/10668/19676
UL http://hdl.handle.net/10668/19676
LA en
DS RISalud
RD Apr 18, 2025